CN109090620B - Mussel polysaccharide and application of degradation product thereof - Google Patents
Mussel polysaccharide and application of degradation product thereof Download PDFInfo
- Publication number
- CN109090620B CN109090620B CN201810903761.6A CN201810903761A CN109090620B CN 109090620 B CN109090620 B CN 109090620B CN 201810903761 A CN201810903761 A CN 201810903761A CN 109090620 B CN109090620 B CN 109090620B
- Authority
- CN
- China
- Prior art keywords
- mussel
- polysaccharide
- mussel polysaccharide
- regulating
- degradation product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000237536 Mytilus edulis Species 0.000 title claims abstract description 61
- 235000020638 mussel Nutrition 0.000 title claims abstract description 58
- 150000004676 glycans Chemical class 0.000 title claims abstract description 49
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 48
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 48
- 239000007857 degradation product Substances 0.000 title abstract description 10
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 21
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 241000192125 Firmicutes Species 0.000 claims description 8
- 241000605059 Bacteroidetes Species 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 18
- 230000001105 regulatory effect Effects 0.000 abstract description 13
- 230000000813 microbial effect Effects 0.000 abstract description 10
- 235000013406 prebiotics Nutrition 0.000 abstract description 9
- 241000700159 Rattus Species 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 6
- 235000013402 health food Nutrition 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 238000006116 polymerization reaction Methods 0.000 abstract description 4
- 241000606125 Bacteroides Species 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 9
- 235000009200 high fat diet Nutrition 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241001546092 Coprophilus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides an application of mussel polysaccharide and its degradation product in regulating intestinal microbial flora; and the application in preparing food, health food or medicine for regulating the intestinal microbial flora of human bodies and feed or medicine for regulating the intestinal microbial flora of animals; and provides a food, health food, feed and medicine containing mussel polysaccharide and its degradation product for regulating intestinal microbial flora. The molecular weight range of the mussel polysaccharide is 2 KDa-400 KDa; the degradation product is mussel oligosaccharide with molecular weight range of 300 Da-2 KDa and polymerization degree of 2-10. The mussel polysaccharide serving as the prebiotic raw material is extracted from marine animals mussels, has rich raw material sources and low production and preparation cost, can obviously reduce the proportion of the Ongyemen of obese model rats, improves the proportion of bacteroides, plays a role in improving the intestinal microecology, and is a novel prebiotic.
Description
Technical Field
The invention belongs to the field of application of natural products, and particularly relates to application of mussel polysaccharide and degradation products thereof in regulating intestinal microbial flora.
Background
With the development of the study of intestinal microbiology, the importance of the balance of intestinal microflora to health is gradually recognized. Research shows that intestinal microorganisms have corresponding characteristics in different stages of human development and fully influence physiological functions. In the aging process of human body, the reduction of movement, the change of nutrition, the change of medicine and living condition can all affect the microorganism and the product thereof, and bring the change of physiological and immune state. The human self genome is difficult to change, but the microbiome can be intervened and regulated by a plurality of means such as coprophilus transplantation, prebiotics/bacteria, antibiotics and the like.
Currently, prebiotics can be classified into the following categories: polysaccharides such as Atractylodis rhizoma polysaccharide, Sargassum polysaccharide, and edible fungus polysaccharide; functional oligosaccharides such as fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, etc.; there are also some natural plants including vegetables, herbs, wild plants, etc. However, there are few reports on the development of marine shellfish polysaccharide or oligosaccharide as prebiotics.
Mussel polysaccharide is from mussels, mussels are an important species in marine shellfish culture, are also called as sea red and are commonly called as 'eggs in the sea', have high medicinal and edible value, and are recorded in Ben Cao gang mu and Ben Cao Shi Yi, and are mainly used for treating diseases such as fatigue emaciation, dizziness, impotence and lumbago. Chinese patent (CN 101357952A) discloses the application of mussel polysaccharide in preparing hypolipidemic drugs or foods; chinese patent (CN 101991038A) discloses the application of mussel polysaccharide in health food with cholesterol-reducing, radioprotective and heavy metal-removing effects; chinese patent (CN 106749718A) discloses an industrialized extraction method of mussel polysaccharide and its application in preparing blood lipid regulating medicine or food; however, no report is found about the application of mussel polysaccharide as prebiotics.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides the application of mussel polysaccharide and mussel oligosaccharide as intestinal prebiotics, which can maintain the ratio of bacteroidetes and firmicutes in intestines at a normal level under high fat intake conditions.
In order to achieve the purpose, the invention adopts the following technical scheme.
Use of mussel polysaccharide and its degradation product in regulating intestinal microbial flora is provided.
Use of mussel polysaccharide and its degradation product in preparing food, health food or medicine for regulating intestinal microbial flora of human body and feed or medicine for regulating intestinal microbial flora of animals is provided.
A food, health food, feed and medicine containing mussel polysaccharide and/or its degradation product for regulating intestinal microbial flora are provided.
The molecular weight range of the mussel polysaccharide is 2 KDa-400 KDa. The mussel polysaccharide is prepared from mussels as an extraction raw material.
The degradation product is mussel oligosaccharide with molecular weight range of 300 Da-2 KDa and polymerization degree of 2-10. Such degradation includes, but is not limited to, microbial degradation, enzymatic degradation, acid degradation, alkaline degradation, ultrasonic degradation, and high temperature degradation.
The invention has the beneficial effects that:
the raw materials of the mussel polysaccharide and the mussel oligosaccharide are easy to obtain, and the mussel polysaccharide and the mussel oligosaccharide have very obvious prebiotic effects. Animal experiments prove that the mussel polysaccharide and the mussel oligosaccharide can maintain the ratio of enterobacteroidetes and firmicutes at a normal level under high fat intake conditions.
Drawings
FIG. 1 is a graph of the regulatory effects of mussel polysaccharide and mussel oligosaccharide on high fat diet-induced imbalance of the intestinal flora.
Detailed Description
The present invention will be further described with reference to the following examples and drawings, but the present invention is not limited to the following examples.
Example 1 preparation of mussel polysaccharide
The frozen and cooked thick-shell dried mussels are taken as raw materials, crushed by a crusher and sieved by a 20-mesh sieve to obtain dried mussel powder; putting mussel dry powder into an extraction tank, adding 6 times of water, extracting at 100 ℃ for 2 hours, and rotating the stirring paddle at the speed of 60 r/min; separating mussel meat residue and polysaccharide extract with 50 mesh screen; adjusting the pH of the prepared polysaccharide extracting solution to 8.0 by using NaOH, adding 0.2% of alkaline protease by mass, carrying out enzymolysis for 2 hours at 50 ℃, and inactivating for 15 minutes at 80 ℃ after the enzymolysis is finished to obtain an enzymolysis solution; using diatomite as a filter aid, and filtering the obtained enzymolysis liquid by using a plate frame to obtain a clear polysaccharide solution, wherein the dosage of the diatomite is 2 kilograms per square meter; adding 1.5 times of ethanol with the volume mass fraction of 93% into the obtained clarified polysaccharide filtrate to perform polysaccharide precipitation, standing for 6 hours, and extracting supernatant to obtain polysaccharide precipitate; adding 1 volume of 93 percent ethanol into the prepared polysaccharide precipitate to dehydrate the polysaccharide precipitate; filtering the dehydrated polysaccharide precipitate by using a 400-mesh screen, collecting the precipitate, and drying in vacuum at 60 ℃ to obtain the white mussel polysaccharide with the molecular weight of 120-K150 KDa.
Example 2 preparation of Mytilus edulis oligosaccharide
Adding water into mussel polysaccharide in the embodiment 1 to prepare a 10% solution, adjusting the pH value to 6.0 by HCl to obtain a mussel polysaccharide solution, adding alpha-amylase into the 10% mussel polysaccharide aqueous solution according to the proportion of 220U/L, preserving the temperature at 30 ℃ for 10 h, inactivating at 100 ℃ for 15 min, filtering by using a 0.22 mu m filter membrane, collecting filtrate, concentrating and freeze-drying to obtain the mussel oligosaccharide crude extract. Taking a proper amount of mussel oligosaccharide crude extract, dissolving with deionized water to obtain a solution with the concentration of 0.5 g/mL, loading the solution onto a polyacrylamide Gel Bio-Gel P-2 column (2.5 cm multiplied by 125 cm), separating with deionized water as an eluent at the flow rate of 37.5 mL/h, collecting for 1 time every 8 min, tracing and detecting by adopting a phenol-sulfuric acid method to draw an elution curve, detecting the polymerization degree of a collected solution by TLC, combining oligosaccharide peak positions with the polymerization degree of 4-6, concentrating the collected solution, and freeze-drying to obtain the mussel oligosaccharide with the molecular weight of 700-1200 Da.
Example 3 Effect of mussel polysaccharides, Mytilus edulis oligosaccharides on intestinal flora
24 male SD rats with the body weight of 140-. After 7 days of quarantine of all rats, 2 groups were randomized by body weight, 6 of them were given as a maintenance diet blank control, 18 were given as high-fat diets, and after 2 weeks of administration of high-fat diets, three groups were randomized by body weight, and high-fat diets were continued, wherein 600 mg/kg/d of mussel polysaccharide was gavaged in one group, 200 mg/kg/d of mussel oligosaccharide was given in one group, and purified water of the same volume was gavaged in the other group.
Wherein the high fat feed formula comprises 67.5% maintenance feed, 10% lard, 10% egg yolk powder, 10% sucrose, 2% cholesterol and 0.5% cholate.
After 6 weeks of mussel polysaccharide administration, each group of rats was sacrificed, their cecal contents were taken, subjected to amplification sequencing using 16S rDNA V3-V4 target regions, and subjected to operational task nanoparticles units (OTU) cluster analysis to compare the differences in the flora structure of the normal group, high-fat diet group, mussel polysaccharide group and mussel oligosaccharide group. Differential flora abundance analysis as shown in figure 1: in the intestinal flora of rats fed with high-fat diet, the proportion of bacteroidetes is significantly reduced (P <0.05) and the proportion of firmicutes is significantly increased (P <0.05) compared to normal rats. The ratio of bacteroidetes and firmicutes in rats fed high fat diet was similar to that in normal rats, with mussel polysaccharide or mussel oligosaccharide intervention. The Bacteroides and the firmicutes are the dominant bacteria in human intestinal tracts, and researches have fully proved that the Bacteroides proportion is reduced and the firmicutes proportion is increased under the conditions of non-alcoholic fatty liver disease, obesity and the like. Therefore, the mussel polysaccharide and the mussel oligosaccharide play a very beneficial role in regulating the intestinal flora, can improve the intestinal microecology, and are novel prebiotics.
Claims (2)
1. Use of mussel polysaccharide in the manufacture of a product for maintaining the ratio of bacteroidetes and firmicutes in the gut at normal levels under conditions of high fat intake, wherein the mussel polysaccharide has a molecular weight in the range of 120 KDa to 150 KDa.
2. Use of mussel oligosaccharides in the manufacture of a product for maintaining the ratio of bacteroidetes and firmicutes in the gut at normal levels under conditions of high fat intake, wherein the mussel oligosaccharides have a molecular weight in the range 700 Da to 1200 Da and a degree of polymerisation in the range 4 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810903761.6A CN109090620B (en) | 2018-08-09 | 2018-08-09 | Mussel polysaccharide and application of degradation product thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810903761.6A CN109090620B (en) | 2018-08-09 | 2018-08-09 | Mussel polysaccharide and application of degradation product thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109090620A CN109090620A (en) | 2018-12-28 |
| CN109090620B true CN109090620B (en) | 2022-02-22 |
Family
ID=64849013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810903761.6A Active CN109090620B (en) | 2018-08-09 | 2018-08-09 | Mussel polysaccharide and application of degradation product thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109090620B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111004294A (en) * | 2019-12-31 | 2020-04-14 | 山东省药学科学院 | Preparation method of mussel oligosaccharide single component MOS-1 |
| CN112089734A (en) * | 2020-09-28 | 2020-12-18 | 广东海洋大学 | Application of mussel extract in preparation of medicament for treating flora disorder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768599A (en) * | 2004-11-03 | 2006-05-10 | 中国科学院大连化学物理研究所 | Healthy polysaccharide food come from sea invertebrate |
| CN101455676A (en) * | 2009-01-05 | 2009-06-17 | 中国人民解放军第二军医大学 | Use of mussel polysaccharide in preparing anti-aging medicine or food |
| CN108354086A (en) * | 2017-12-29 | 2018-08-03 | 磐安县派普特生物科技有限公司 | Preparation method containing mussel polysaccharide prawn phagostimulant |
-
2018
- 2018-08-09 CN CN201810903761.6A patent/CN109090620B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768599A (en) * | 2004-11-03 | 2006-05-10 | 中国科学院大连化学物理研究所 | Healthy polysaccharide food come from sea invertebrate |
| CN101455676A (en) * | 2009-01-05 | 2009-06-17 | 中国人民解放军第二军医大学 | Use of mussel polysaccharide in preparing anti-aging medicine or food |
| CN108354086A (en) * | 2017-12-29 | 2018-08-03 | 磐安县派普特生物科技有限公司 | Preparation method containing mussel polysaccharide prawn phagostimulant |
Non-Patent Citations (2)
| Title |
|---|
| 海洋生物多糖在肠内营养制剂中的应用;蔡冰娜等;《肠外与肠内营养》;20100310(第02期);第110-111页 * |
| 海洋贝类多糖的研究进展;刘志昌等;《食品安全质量检测学报》;20171125(第11期);第4231-4238页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109090620A (en) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Macrofungi: A review of cultivation strategies, bioactivity, and application of mushrooms | |
| US10293008B2 (en) | Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof | |
| CN109090620B (en) | Mussel polysaccharide and application of degradation product thereof | |
| AU2016279383B2 (en) | Method for producing fermented bamboo extract and immunostimulator | |
| GIaVaSIS | Polysaccharides from medicinal mushrooms for potential use as nutraceuticals | |
| JP4671450B1 (en) | Diet food | |
| JP6742981B2 (en) | Immunomodulator and its use | |
| JP5081485B2 (en) | Anticancer agent and method for producing anticancer agent | |
| CN107227327B (en) | Preparation method of mussel oligosaccharide, and product and application thereof | |
| CN111109413A (en) | Method for producing tartary buckwheat fungus tea by using phellinus igniarius | |
| CA3010529C (en) | Ester of aminoglycan and uses thereof | |
| CN113749185A (en) | Novel functional feed for lithocarpus polystachyus and preparation method thereof | |
| CN114376068A (en) | Fermented garlic liquid for drinking water of livestock and poultry and preparation method thereof | |
| CN106690326B (en) | Compound algal polysaccharide blood fat reducing oral liquid and preparation method thereof | |
| CN107455605B (en) | Feed compound for reducing cholesterol content of egg yolk | |
| Michael et al. | Marine polysaccharides: properties and applications | |
| CN111084231A (en) | High-activity corn stigma compound polysaccharide and preparation method thereof | |
| CN117981875B (en) | Lactobacillus reuteri Gly LR15 composition with immunity improving function and preparation method thereof | |
| KR20200112148A (en) | Prebiotics composition for improving intestinal microflora comprising garlic peel extract and funtional food comprising the same | |
| CN117257818A (en) | Inulin composition for regulating body weight | |
| US11839640B2 (en) | Prebiotic composition and methods for using the same | |
| CN115040559B (en) | Traditional Chinese medicine microecological preparation for feed and application | |
| CN114391648B (en) | Preparation method of probiotic fermented oat composition with blood sugar and blood lipid reducing effects | |
| KR20120132646A (en) | Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity | |
| JP2018050488A (en) | Immunostimulatory composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220113 Address after: No. 989 Xinlu Street, Jinan City, Shandong Province, 250101 Applicant after: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES Applicant after: Shenzhen Research Institute of Xiamen University Address before: 250101 No. 989, Xinluo street, Lixia District, Jinan City, Shandong Province Applicant before: SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |